309 related articles for article (PubMed ID: 25504149)
1. Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target.
Jackson M; Hassiotou F; Nowak A
Carcinogenesis; 2015 Feb; 36(2):177-85. PubMed ID: 25504149
[TBL] [Abstract][Full Text] [Related]
2. Glioblastoma and stem cells.
Altaner C
Neoplasma; 2008; 55(5):369-74. PubMed ID: 18665745
[TBL] [Abstract][Full Text] [Related]
3. Co-expression of Cytoskeletal Protein Adducin 3 and CD133 in Neurospheres and a Temozolomide-resistant Subclone of Glioblastoma.
Poon MW; Zhuang JT; Wong ST; Sun S; Zhang XQ; Leung GK
Anticancer Res; 2015 Dec; 35(12):6487-95. PubMed ID: 26637861
[TBL] [Abstract][Full Text] [Related]
4. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro.
Huang Q; Zhang QB; Dong J; Wu YY; Shen YT; Zhao YD; Zhu YD; Diao Y; Wang AD; Lan Q
BMC Cancer; 2008 Oct; 8():304. PubMed ID: 18940013
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.
Ma HI; Chiou SH; Hueng DY; Tai LK; Huang PI; Kao CL; Chen YW; Sytwu HK
J Neurosurg; 2011 Mar; 114(3):651-62. PubMed ID: 21054139
[TBL] [Abstract][Full Text] [Related]
6. ADAM17 regulates self-renewal and differentiation of U87 glioblastoma stem cells.
Chen X; Chen L; Zhang R; Yi Y; Ma Y; Yan K; Jiang X; Wang X
Neurosci Lett; 2013 Mar; 537():44-9. PubMed ID: 23356982
[TBL] [Abstract][Full Text] [Related]
7. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy.
Tamura K; Aoyagi M; Ando N; Ogishima T; Wakimoto H; Yamamoto M; Ohno K
J Neurosurg; 2013 Nov; 119(5):1145-55. PubMed ID: 23991844
[TBL] [Abstract][Full Text] [Related]
8. A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, suppresses stemness in glioma stem-like cells.
Kim RK; Kim MJ; Yoon CH; Lim EJ; Yoo KC; Lee GH; Kim YH; Kim H; Jin YB; Lee YJ; Cho CG; Oh YS; Gye MC; Suh Y; Lee SJ
Mol Pharmacol; 2012 Sep; 82(3):400-7. PubMed ID: 22648970
[TBL] [Abstract][Full Text] [Related]
9. Glioblastoma cancer stem cells--from concept to clinical application.
Stopschinski BE; Beier CP; Beier D
Cancer Lett; 2013 Sep; 338(1):32-40. PubMed ID: 22668828
[TBL] [Abstract][Full Text] [Related]
10. Cell death and neuronal differentiation of glioblastoma stem-like cells induced by neurogenic transcription factors.
Guichet PO; Bieche I; Teigell M; Serguera C; Rothhut B; Rigau V; Scamps F; Ripoll C; Vacher S; Taviaux S; Chevassus H; Duffau H; Mallet J; Susini A; Joubert D; Bauchet L; Hugnot JP
Glia; 2013 Feb; 61(2):225-39. PubMed ID: 23047160
[TBL] [Abstract][Full Text] [Related]
11. Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy.
Spencer DA; Auffinger BM; Murphy JP; Muroski ME; Qiao J; Gorind Y; Lesniak MS
Curr Cancer Drug Targets; 2017; 17(3):236-254. PubMed ID: 27993114
[TBL] [Abstract][Full Text] [Related]
12. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.
Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R
Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372
[TBL] [Abstract][Full Text] [Related]
13. Cancer: stem cells and brain tumours.
Dirks PB
Nature; 2006 Dec; 444(7120):687-8. PubMed ID: 17151644
[No Abstract] [Full Text] [Related]
14. Targeting brain-tumor stem cells.
Stupp R; Hegi ME
Nat Biotechnol; 2007 Feb; 25(2):193-4. PubMed ID: 17287755
[No Abstract] [Full Text] [Related]
15. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.
Soeda A; Park M; Lee D; Mintz A; Androutsellis-Theotokis A; McKay RD; Engh J; Iwama T; Kunisada T; Kassam AB; Pollack IF; Park DM
Oncogene; 2009 Nov; 28(45):3949-59. PubMed ID: 19718046
[TBL] [Abstract][Full Text] [Related]
16. CD133 is essential for glioblastoma stem cell maintenance.
Brescia P; Ortensi B; Fornasari L; Levi D; Broggi G; Pelicci G
Stem Cells; 2013 May; 31(5):857-69. PubMed ID: 23307586
[TBL] [Abstract][Full Text] [Related]
17. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme.
Pallini R; Ricci-Vitiani L; Banna GL; Signore M; Lombardi D; Todaro M; Stassi G; Martini M; Maira G; Larocca LM; De Maria R
Clin Cancer Res; 2008 Dec; 14(24):8205-12. PubMed ID: 19088037
[TBL] [Abstract][Full Text] [Related]
18. A brain tumor stem cell origin for glioblastoma endothelium.
Turner JD; Sanai N
World Neurosurg; 2011; 75(5-6):574-5. PubMed ID: 21704909
[No Abstract] [Full Text] [Related]
19. Cancer stem cells from human glioma cell line are resistant to Fas-induced apoptosis.
Bertrand J; Begaud-Grimaud G; Bessette B; Verdier M; Battu S; Jauberteau MO
Int J Oncol; 2009 Mar; 34(3):717-27. PubMed ID: 19212677
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma.
Pistollato F; Abbadi S; Rampazzo E; Persano L; Della Puppa A; Frasson C; Sarto E; Scienza R; D'avella D; Basso G
Stem Cells; 2010 May; 28(5):851-62. PubMed ID: 20309962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
